scholarly journals Effect of Calcium Channel Blockers on Lower Urinary Tract Symptoms: A Systematic Review

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Muhammad Salman ◽  
Amer Hayat Khan ◽  
Syed Azhar Syed Sulaiman ◽  
Junaid Habib Khan ◽  
Khalid Hussain ◽  
...  

Background. Numerous medications are known to be associated with the development of lower urinary tract symptoms (LUTS). One such medication group is calcium channel blockers (CCB). Objective. To critically examine the literature regarding the involvement of CCB in manifestation of LUTS in humans. Methods. A systematic literature search was conducted on PubMed, SciELO, Scopus, and OpenGrey databases to find all potentially relevant research studies before August 2016. Results. Five studies met the inclusion criteria and were included in this review. Three out of five studies stated that CCB were involved in either precipitation or exacerbation of LUTS. As for the remaining two studies, one study found out that only the monotherapy of CCB was associated with increased prevalence of nocturia and voiding symptoms in young females, whereas the other study reported an inverse association of CCB with LUTS. The methodological quality of studies was considered high for four studies and low for one study. Conclusion. Healthcare providers should make efforts for an earlier identification of the individuals at risk of LUTS prior to the commencement of CCB therapy. Moreover, patients should be counselled to notify their healthcare provider if they notice urinary symptoms after the initiation of CCB.

2021 ◽  
Vol 11 (6) ◽  
pp. 712
Author(s):  
Mikolaj Przydacz ◽  
Marcin Chlosta ◽  
Tomasz Golabek ◽  
Piotr Chlosta

Background: The aim of this study was to perform a cross-sectional study of Polish neurogenic patients to measure, at the population level, the prevalence, bother and behavior associated with treatment for lower urinary tract symptoms (LUTS) and overactive bladder (OAB). Methods: This epidemiological study was based on data from LUTS POLAND, a computer-assisted and population-representative telephone survey. Participants were classified by age, sex and place of residence. Results: LUTS POLAND includes 6005 completed interviews, of which 1166 (19.4%) were for individuals who had ever received any treatment by neurologists and/or neurosurgeons. Among these neurogenic participants, LUTS prevalence was 72.3%, statistically higher than for non-neurogenic respondents. At the population level, neurogenic patients had about a 20% higher risk for LUTS presence than non-neurogenic participants (relative risk: 1.17–1.21). LUTS prevalence did not differ between men and women. Frequency was the most common of the LUTS. Forty percent of neurogenic respondents described having more than one LUTS subtype (i.e., storage, voiding, and/or post-micturition symptom subtype), and more than 50% of respondents reported OAB symptoms. Both storage and voiding symptoms were bothersome, and many neurogenic individuals (42.3–51.0%) expressed anxiety about bladder function affecting quality of life. Only one-third (34.9–36.6%) of neurogenic participants had sought treatment for their LUTS, and the majority of such individuals received and maintained treatment. Conclusions: LUTS and OAB symptoms were highly prevalent and bothersome among Polish neurogenic patients at the population level. Because the scale of seeking treatment for LUTS was low, Polish neurogenic patients may not be adequately informed about multiple effects of LUTS and OAB.


2016 ◽  
Vol 23 (11) ◽  
pp. 1340-1344
Author(s):  
Mumtaz Rasool ◽  
Muhammad Shahzad Saleem ◽  
Muhammad Waqas ◽  
Mudassar Saeed Pansota ◽  
Shafqat Ali Tabassum

Introduction: Lower urinary tract symptoms are one of the commonestpresentation in urology clinics. Lower Urinary tract symptoms include storage symptoms(frequency, urgency, urge incontinency and nocturia), voiding symptoms (hesitancy, dysuria,intermittency, poor stream of urine, terminal dribbling and residual urine sensation). Correctdetermination of prevalence of LUTS might help the health service provider to plan appropriatemanagement strategies. So this study was designed to determine frequency of LUTS in menaged 40 or above. Study Design: Descriptive, cross sectional study. Period: January 2015to December 2015. Setting: Urology Department of Bahawal Victoria Hospital, Bahawalpur.Materials & Methods: Total 228 patients of 40-80 years of age with lower urinary tract symptomswere included. Patients with foleys in situ, previously operated for urinary tract disease, urinarytract stones and urinary bladder mass were excluded. These patients were assessed todetermine frequency of lower urinary tract symptoms. Results: Mean age was 65.69 ± 7.91years. Mean duration of disease was 5.36 ± 2.19 months. Frequency of LUTS was seen in 138(60.53%) men with urgency in 22.81%, nocturia in 57.89%, frequency in 19.30%, poor streamin 15.79%, incomplete emptying of bladder in 33.33%, urge incontinence in 22.81%, terminaldribbling in 55.26% and hesitancy in 15.16% men. Conclusion: This study concluded thatthe frequency of lower urinary tract symptoms were urgency in 22.81%, nocturia in 57.89%,frequency in 19.30%, poor stream in 15.79%, incomplete emptying of bladder in 33.33%, urgeincontinence in 22.81%, terminal dribbling in 55.26% and hesitancy in 15.16% patients of age≥40 years with nocturia being the most common symptom and frequency of all symptomsincreases with age.


2012 ◽  
Vol 79 (1) ◽  
pp. 19-23 ◽  
Author(s):  
Elisabetta Costantini ◽  
Massimo Lazzeri ◽  
Massimo Porena

Background Female pelvic organ prolapse (POP) is a common condition that often leads to lower urinary tract symptoms (LUTS) and may require surgical intervention to alleviate those symptoms. However, tThe relationship between LUTS and pelvic organ descent however, remains unclear. The aim of this paper is to determine the correlation between LUTS and POP and changes after POP repair. Methods We retrospectively review female patients who attended our tertiary high- volume centre center for LUTS and POP, and underwent integral pelvic floor reconstruction. Results An overall of 256 patients presented with POP and LUTS and underwent POP repair. Most of 50% of patients reported two or more symptoms and only 4.2% were asymptomatic for LUTS. 189/256 (73.8%) patients had voiding symptoms and 39 a urodynamic detrusor overactivity. Thirteen suffered from hydronephrosis. 148/256 (57.8%) showed a stress urinary incontinence. All the patients underwent POP repair with or without contemporary anti- incontinence procedure. Conclusions Urologists and gynaecologists should recognisebe aware of the high frequency of the POP and LUTS association of POP and LUTS. POP repair my restore a normal situation but symptoms may last after the surgery or develop “de novo.”


2007 ◽  
Vol 98 (6) ◽  
pp. 1237-1242 ◽  
Author(s):  
Samuel Y. S. Wong ◽  
Winny W. Y. Lau ◽  
Ping C. Leung ◽  
Jason C. S. Leung ◽  
Jean Woo

The objective of the present study is to explore the association between lower urinary tract symptoms (LUTS) and dietary isoflavone in elderly men. In a large prospective cohort of 2000 Chinese men, the association between dietary isoflavone and LUTS were studied using standardized structured questionnaires. Dietary intake was assessed by a modified version of the Block FFQ. LUTS were assessed by the Chinese version of the International Prostatic Symptoms Score. Demographic, lifestyle and other medical information were also collected and were adjusted for in the analysis. After excluding 299 men with history of bladder surgery, bladder or prostate cancer or who were current users of medication for urinary problems, the association between LUTS and dietary isoflavone was explored. A total of 96·2 % of subjects reported some consumption of genistein, glycitein or daidzein. In ordinal multinominal logistic regression, subjects with dietary total isoflavone of more than 5·1 mg were significantly less likely to suffer from more severe LUTS (dietary intake from 5·1 to 9·5 mg: OR 0·59; 95 % CI 0·44, 0·80; from 9·6 to 14·3 mg: OR 0·81; 95 % CI 0·61, 1·09; from 14·4 to 21·7 mg: OR 0·68; 95 % CI 0·51, 0·92; 21·8 mg and above: OR 0·73; 95 % CI 0·54, 0·98) after adjustment for covariates. In this cross-sectional study, we showed a strong inverse association between dietary intake of isoflavone and the risk of LUTS.


Author(s):  
Mikolaj Przydacz ◽  
Przemyslaw Dudek ◽  
Tomasz Golabek ◽  
Piotr Chlosta

Background: The aim of this study was to investigate the effect of lower urinary tract symptoms (LUTS) on behavior related to treatment of Polish adults aged ≥ 40 years. Methods: We conducted a computer-assisted telephone survey with a study sample stratified by age, sex, and place of residence (type, size, urban versus rural) reflecting the entire Polish population. Participants rated the frequency and symptom-specific bother of individual LUTS and their effects on seeking and receiving treatment, treatment satisfaction, and treatment continuation. We adjusted multiple logistic regression models to analyze the simultaneous effects of predictor variables on each dependent variable. Results: Overall, 6005 participants completed the interview. One third (29.6–33.5%) of participants with LUTS were seeking treatment, and 24.0–26.4% received treatment. There was no difference in treatment seeking and receiving between urban and rural areas. Whereas storage and voiding symptoms were significantly related to treatment seeking by both men and women, treatment receiving correlated only with voiding symptoms in men and only with storage symptoms in women. Most respondents who received treatment were satisfied; treatment dissatisfaction was related to the presence of storage symptoms in both men and women. Only 50% of all participants continued their treatment; discontinuation of treatment was statistically more prevalent for women than for men. Conclusion: This investigation, the first population-representative study performed in Eastern Europe, revealed a low frequency of seeking treatment for LUTS. In addition, symptoms that inclined participants to seek treatment might not have been adequately addressed by the treatment they received. We also found a relatively high rate of treatment discontinuation. Clearly, there is a need for both improved patient education about LUTS treatment and a need for increased clinician awareness of the coexistence of different symptoms in men and women plus proactive evaluation by physicians for all types of LUTS and associated bother.


Author(s):  
Bindu Sharma ◽  
Raj K Machandra ◽  
Pritha Mehra ◽  
Parveen Oberai ◽  
Varanasi Roja ◽  
...  

Background: Benign Prostatic Hyperplasia (BPH) associated with Lower Urinary Tract Symptoms (LUTS) is the most common condition in ageing men. The epidemiological studies estimate that 90% of men between 45 and 80 years of age suffer some type of LUTS.1 There is paucity of such epidemiological data from India but one study reports the prevalence of BPH among rural elderly of India as 11.8%2. Although LUTS secondary to BPH (LUTS/BPH) is not often a life-threatening condition, the impact of LUTS/BPH and its complications on Quality of Life (QoL) can be significant and should not be underestimated.3 When the effect of BPH-associated LUTS on QoL was studied in a number of community-based populations, for many, the most important motivations for seeking treatment were the severity and the degree of bother associated with the symptoms.4LUTS include storage and/or voiding disturbances common in ageing men. Although voiding symptoms are most common, storage symptoms responsible for daytime frequency, urgency and nocturia interfere the most with life activities. Homoeopathic constitutional treatment is useful in the treatment of a constellation of symptoms due to BPH and LUTS. Along with constitutional medicine homoeopathic practitioners are using organ medicines having special affinity for prostate and urinary bladder with good results. Traditionally the primary goal of treatment is to alleviate bothersome LUTS that result from prostatic enlargement. The literature review indicates that both homoeopathic constitutional medicines as well as organ specific remedies show positive results in relieving the symptoms of BPH but the study was not randomized and there was no control group to show its efficacy. In this backdrop the present study was undertaken to evaluate the storage and voiding symptoms of men having BPH through an internationally validated scale IPSS and the role of homoeopathic intervention, both constitutional and organ remedies on LUTS due to BPH and QoL of the patient. Objectives: The primary objective was to compare the changes in IPSS (International Prostate Symptom Score) within the three groups enrolled for the study (Constitutional remedy/Constitutional + Organ remedy/Placebo). The secondary objectives were to compare the changes in Prostate volume, Post Void Residual Urine (PVRU), Uroflowmetry and in WHOQOL-BREF.5 Material and Methods: The study was done in an open randomized placebo controlled setting at five research centers under Central Council for Research in Homoeopathy. The patients in the age group of 50-80 years presenting with the symptoms of incomplete emptying, frequency, intermittency, urgency, weak stream, straining and nocturia were screened from the general OPD as per ICD-10 Classification Code N40.0 following the predefined inclusion and exclusion criteria. A consultant Urologist was appointed at each center to screen and follow up the enrolled cases. The participants who qualified the inclusion criteria were enrolled in the study after obtaining the ‘Informed Written Consent’. It was a three armed randomized clinical trial where Intervention was administered as per the randomization chart for three groups i.e. homoeopathic constitutional medicine in LM potency (Group 1), homoeopathic constitutional medicine in LM potency with organ remedy in mother tincture and 3X (Group 2) and placebo (Group 3) in 2:2:1 ratio. The patients were followed for six months and the outcome of intervention was assessed monthly for IPSS (Primary objective) and at third and sixth month for prostate volume, post void residual urine, Qmax and Qavg, PSA and WHOQOL-BREF, (Secondary objectives). Internationally validated scales (IPSS &WHOQOL-BREF) were used to assess the outcome. Primary safety endpoint was any adverse event which may be life threatening, requires prolonged hospital stay, results in significant disability, an injury, accident or any other important medical event. 474 patients were screened and 252 patients were enrolled in the study. The analysis of these patients as per protocol and as per intention to treat was carried out using repeated measures ANOVA and paired T test. Results: Out of 254 patients enrolled in the study (HC=103, HC + O = 102 and Placebo = 49), 152 were analyzed as per protocol (HC=71, HC + O = 53 and Placebo = 28) as they completed a follow up period of 6 months whereas, 241 patients were analyzed as per ITT (HC=101, HC + O = 92 and Placebo = 48). 13 patients were excluded from analysis for reasons such as protocol violation and incomplete baseline information. There was statistically significant improvement in all the seven components of IPSS, WHOQOL- BREF and Q max values of uroflowmetry in both per protocol as well as ITT analysis. Discussion: Results from this trial will help in constructing treatment strategy for BPH patients with lower urinary tract symptoms to enable them to make an informed decision about available alternatives for the management of LUTS in BPH. The limitation of the study was that it was not blinded. The inhibition for not making it blinded was the use of mother tinctures of organ specific medicines in liquids of different colors and odours which could not be blinded. Pragmatic trial with longer follow up and a parallel arm comprising of conventional treatment may be undertaken in future to compare their role on LUTS due to BPH on pathological and pathophysiological parameters such as prostatic volume and post void residual urine. Trial Registration: Clinical Trial Registry - India: CTRI/2012/05/002649.


2021 ◽  
Vol 93 (4) ◽  
pp. 445-449
Author(s):  
Emanuele Rubilotta ◽  
Daniele Castellani ◽  
Marilena Gubbiotti ◽  
Matteo Balzarro ◽  
Giacomo Maria Pirola ◽  
...  

Purpose: To assess the prevalence of nocturnal polyuria (NP) in males performing uroflowmetry (UF) for lower urinary tract symptoms (LUTS), the impact of NP on UF outcomes, and bladder emptying, the association between NP and LUTS. Materials and methods: Men scheduled for UF were recruited in two Centres. Data collected were medical history, IPSS, UF, post-void residual urine volume (PVR), 3-day frequency-volume charts (FVC). The NP index was used to assess NP with a threshold of ≥ 33%. The relationship between NP and patient’s aging was assessed. Results: 162 patients were included in the analysis. Mean age was 70.95 ± 8.04 years. The prevalence of NP was 54.9% (89/162). 110 (68%) patients reported nocturia, and among these, NP was documented in 76 (69%). Nocturia was found in 85% (76/89) of the population with NP. Total IPSS score, IPSS items #1, #2 and #7 showed a significant difference in men with NP compared with those without. Maximum flow rate and PVR did not significantly change comparing men with or without NP. Mean voiding volume (VV) of the night-time micturitions was significantly higher in men with NP compared to those without NP (532.1 ± 275.6 ml vs 175 ± 168.7 ml respectively, p < 0001), while mean VV day-time micturitions and mean VV at UF did not change between groups.Conclusions: NP had a high prevalence in men with LUTS performing UF. Aged males were more commonly affected by NP. Data demonstrated a strong relationship between NP and nocturia and increased urinary frequency while voiding symptoms were poorly related to NP.


2021 ◽  
Vol 104 (6) ◽  
pp. 1045-1049

The pandemic of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) or Coronavirus Disease 2019 (COVID-19) is still ongoing. The outbreak of this new emerging contagious disease has impacted a wide range of sectors including health and economics. Much information about COVID-19 has been discovered by many laboratories, and action taken in various ways as quickly as possible to inhibit the outbreak. It was found that COVID-19 is a ribonucleic acid virus (RNA virus) that can cause infection among humans. Moreover, it can mutate and spread contagiously mainly through the respiratory system. The most common symptoms are cough and fever. Many patients could develop to either pneumonitis or respiratory failure. The SARS-CoV-2 virus can infect various organs, the main infections being in lungs and rectum. In these cases, many laboratories can isolate the virus from oropharyngeal and nasopharyngeal swab and then apply the reverse transcription polymerase chain reaction (RT-PCR) test to identify the COVID-19 virus. Many of the viral infections can cause cystitis by immunologic response. There is a study that showed the SARS-CoV-2 virus could be isolated from the urine sample. The patients had significant changes in urinary storage for frequency, urgency, and urinary incontinence during infected period, which improved after the disease resolved. Moreover, there is a study that reported that the COVID-19 patients who had the International Prostate Symptom Score (IPSS) scores of 20 to 35 had significantly longer hospital stays, more frequent intensive care requirements, and higher mortality rates. Therefore, physician and medical personnel should be aware of the irritative voiding symptoms that might be the presenting symptoms of COVID-19. Furthermore, as many studies have shown that the virus can be excreted in urine, thus, the virus could be contagious via urinary contamination. Keywords: COVID-19; LUTS, Lower urinary tract symptoms; Viral cystitis


2017 ◽  
Vol 10 (2) ◽  
pp. 79-92 ◽  
Author(s):  
Mauro Gacci ◽  
Arcangelo Sebastianelli ◽  
Pietro Spatafora ◽  
Giovanni Corona ◽  
Sergio Serni ◽  
...  

Storage lower urinary tract symptoms (LUTS) are characterized by an altered bladder sensation, increased daytime frequency, nocturia, urgency and urgency incontinence. Some evidence underlines the role of metabolic factors, pelvic ischemia, prostatic chronic inflammation and associated comorbidities in the pathophysiology of storage LUTS. A detailed evaluation of the severity of storage LUTS, and the concomitance of these symptoms with voiding and postmicturition symptoms, is mandatory for improving the diagnosis and personalizing treatment. A detailed medical history with comorbidities and associated risk factors, a physical examination, a comprehensive analysis of all the features of LUTS, including their impact on quality of life, and a frequency–volume chart (FVC) or bladder diary, are recommended for men with storage LUTS. Several drugs are available for the treatment of LUTS secondary to benign prostatic obstruction (BPO). Alpha-blockers (α-blockers), 5-α-reductase inhibitors and phosphodiesterase type 5 inhibitors are commonly used to manage storage LUTS occurring with voiding symptoms associated with BPO. Muscarinic receptor antagonists and Beta 3-agonists (β3-agonists) alone, or in combination with α-blockers, represent the gold standard of treatment in men with predominant storage LUTS. There is no specific recommendation regarding the best treatment options for storage LUTS after prostatic surgery.


Sign in / Sign up

Export Citation Format

Share Document